Evidence map›Paper›PMID 24842525›Full record

Trial reportBone marrow transplantation2014

Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

H-L Liu, Z-M Sun, L-Q Geng, X-B Wang, K-Y Ding, J Tong, B-L Tang, C-Y Zhou, W Yao, C-C Zheng and 4 more

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

H-L Liu1] Institute of Clinical Pharmacology, Anhui Medical University, Anhui, China [2] Department of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
Z-M SunDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
L-Q GengDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
X-B WangDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
K-Y DingDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
J TongDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
B-L TangDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
C-Y ZhouDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
W YaoDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
C-C ZhengDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
K-D SongDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
X-Y ZhuDepartment of Hematology of Anhui Provincial Hospital, Anhui Medical University, Anhui, China.
W WeiInstitute of Clinical Pharmacology, Anhui Medical University, Anhui, China.
Y Wang1] Institute of Clinical Pharmacology, Anhui Medical University, Anhui, China [2] Laboratory of Molecular Biology and Department of Biochemistry; Anhui Medical University, Anhui, China [3] Key Laboratory of Anti-inflammatory and Immunological Pharmacology, Ministry of Education, Anhui Medical University, Anhui, China [4] Key Laboratory of Gene Resource Utilization for Severe Diseases of Anhui Province, Anhui Medical University, Anhui, China.
Anhui Medical University · CNAnhui Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study included data from 185 consecutively treated patients, 16 years of age or older, who underwent myeloablative transplantation using unrelated umbilical cord blood (UCB) (UCB transplantation (UCBT), n=70) or HLA-identical sibling donor peripheral blood stem cells alone or combined with bone marrow (BMT/PBSCT, n=115) from October 2001 to December 2012. All patients received myeloablative regimens, cyclosporin A plus mycophenolate mofetil as prophylaxis for GVHD, and similar supportive care. Although hematopoietic recovery was significantly delayed after UCBT, the rate of neutrophil engraftment was comparable. The median follow-up was 53 months (range, 15-136 months) for BMT/peripheral blood SCT (PBSCT) recipients and 35 months (range, 10-123 months) for UCBT recipients. There were no significant differences in the cumulative incidence of grades III to IV acute GVHD, relapse rate, or 3-year probabilities of disease-free survival between patients receiving UCBT and those receiving BMT/PBSCT. However, the cumulative incidence of chronic and extensive chronic GVHD was lower in UCBT recipients. The rates of long-term survivors returning to school or work and off immunosuppressive therapy were significantly higher after UCBT, which indicated that long-term survivors who underwent UCBT had a higher quality of life.

Indexed as

Cord Blood Stem Cell TransplantationHematologic NeoplasmsLiving DonorsQuality of LifeSiblingsUnrelated DonorsAdolescentAdultAllograftsCyclosporineDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansMaleMiddle AgedCyclosporineMycophenolic Acid

Identifiers

PMID24842525
OpenAlexW2018345615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.